imatinib mesylate has been researched along with Coronary Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Audring, H; Baskaynak, G; Dörken, B; Kreuzer, KA; le Coutre, P; Riess, H; Schwarz, M; Zuber, J | 1 |
| Dirschinger, J; Goos, C; Hausleiter, J; Heemann, U; Kastrati, A; Mehilli, J; Pache, J; Pogatsa-Murray, G; Schömig, A; Schühlen, H; Zohlnhöfer, D | 1 |
1 trial(s) available for imatinib mesylate and Coronary Disease
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Benzamides; Coronary Angiography; Coronary Disease; Coronary Restenosis; Creatinine; Double-Blind Method; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Secondary Prevention; Stents | 2005 |
1 other study(ies) available for imatinib mesylate and Coronary Disease
| Article | Year |
|---|---|
Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment.
Topics: Age Factors; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cocarcinogenesis; Coronary Disease; Drug Eruptions; Dyspnea; Enzyme Inhibitors; Facial Neoplasms; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Pancytopenia; Piperazines; Pleural Effusion; Pyrimidines; Sunlight; Ultraviolet Rays | 2003 |